Saniona

Saniona is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies for patients with rare diseases that lack available treatment options. The company's lead candidate, Tesomet, is currently in mid-stage clinical trials for hypothalamic obesity and Prader-Willi syndrome. These severe rare diseases are characterized by significant weight gain, metabolic dysfunction, and uncontrollable hunger.